Myles Minter is ranked #977 on 13Foresight, scored on hit rate, average return versus the market, and number of calls.

Myles Minter

Q: How accurate are Myles Minter's stock ratings?

About 58% of Myles's ratings were profitable over a one-year hold, with an average return of +7.5% per rating, measured by 13Foresight from historical prices.

William Blair

Wall Street Analyst

★★★☆☆

#977

on 13Foresight · ranked by our own returns

59%

Success Rate

+7.5%

Average Return

50 of 85 calls profitable · +4.4% vs benchmark

Time Frame ⓘ

1 Yr 2 Yr 3 Yr 5 Yr

Compared To ⓘ

S&P 500 (SPY)

🔒 5-year track record is Pro. Showing 1-year — upgrade.

📈 Across the calls we could measure, roughly 59% of Myles Minter's ratings turned a profit when each position was held for 1 year — averaging +7.5% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

231 Buy 54 Hold 0 Sell

Myles's Stock Coverage 33 ratings · 2026-08-14

Company	Date	Position	Consensus ⓘ	Price Target ⓘ	1-Yr Return	vs S&P 500 ⓘ
OVID Ovid Therapeutics	Aug 13, 2026	BUY	Strong Buy +81.2% avg upside 18 analysts	—	+1.1%	·
ANRO Alto Neuroscience, Inc.	Aug 13, 2026	BUY	Strong Buy -1.4% avg upside 13 analysts	—	-0.5%	·
IMUX Immunic	Aug 11, 2026	BUY	Strong Buy +132.7% avg upside 21 analysts	—	+0.8%	·
BHVN Biohaven Ltd.	Aug 11, 2026	HOLD	Strong Buy +55.3% avg upside 25 analysts	—	+1.7%	·
BBIO BridgeBio Pharma	Aug 11, 2026	BUY	Strong Buy +16.6% avg upside 34 analysts	—	-4.8%	·
VRTX Vertex Pharmaceuticals	Aug 10, 2026	BUY	Strong Buy -14.1% avg upside 62 analysts	—	+0.4%	·
SLN Silence Therapeutics	Aug 10, 2026	BUY	Strong Buy +143.6% avg upside 10 analysts	—	-11.1%	·
AXSM Axsome Therapeutics	Aug 10, 2026	BUY	Strong Buy +10.5% avg upside 29 analysts	—	-3.3%	·
DNLI Denali Therapeutics	Aug 07, 2026	BUY	Strong Buy +53.8% avg upside 24 analysts	—	-1.7%	·
ARCT Arcturus Therapeutics	Aug 07, 2026	BUY	Buy +274.0% avg upside 36 analysts	—	+2.6%	·
ALEC Alector	Aug 07, 2026	HOLD	Buy +386.2% avg upside 14 analysts	—	+10.1%	·
VTGN VistaGen Therapeutics	Aug 06, 2026	HOLD	Hold +877.3% avg upside 8 analysts	—	-3.6%	·
NTLA Intellia Therapeutics	Aug 06, 2026	BUY	Buy +226.5% avg upside 37 analysts	—	+6.0%	·
XENE Xenon	Aug 06, 2026	BUY	Strong Buy -3.0% avg upside 28 analysts	—	-3.4%	·
KRRO Korro Bio	Aug 06, 2026	BUY	Strong Buy +104.6% avg upside 19 analysts	—	+9.6%	·
MRNA Moderna	Aug 06, 2026	HOLD	Hold +11.5% avg upside 38 analysts	—	+17.6%	·
RAPP Rapport Therapeutics, Inc.	Aug 05, 2026	BUY	Strong Buy +21.1% avg upside 14 analysts	—	+11.7%	·
LRMR Larimar Therapeutics	Aug 05, 2026	BUY	Strong Buy +318.0% avg upside 22 analysts	—	+6.3%	·
TRDA Entrada Therapeutics Inc	Aug 05, 2026	BUY	Strong Buy +186.6% avg upside 10 analysts	—	+5.7%	·
DNTH Dianthus Therapeutics	Aug 04, 2026	BUY	Strong Buy -10.6% avg upside 29 analysts	—	+5.0%	·
CTNM Contineum Therapeutics, Inc. Class A	Jul 31, 2026	BUY	Strong Buy +41.2% avg upside 9 analysts	—	-8.4%	·
NBIX Neurocrine	Jul 31, 2026	BUY	Strong Buy +23.9% avg upside 37 analysts	—	-6.2%	·
ALNY Alnylam Pharma	Jul 30, 2026	BUY	Strong Buy +42.7% avg upside 51 analysts	—	+11.3%	·
BIIB Biogen	Jul 29, 2026	BUY	Strong Buy +20.6% avg upside 52 analysts	—	+0.3%	·
IONS Ionis Pharmaceuticals	Jul 29, 2026	BUY	Strong Buy +41.7% avg upside 43 analysts	—	+5.4%	·
CAMP CAMP4 Therapeutics Corporation	Jul 27, 2026	BUY	Strong Buy +112.7% avg upside 9 analysts	—	+59.1%	·
NMRA Neumora Therapeutics, Inc.	Jul 27, 2026	BUY	Buy +342.5% avg upside 11 analysts	—	-3.6%	·
ARGX Argenx Se	Jun 24, 2026	BUY	Strong Buy -8.7% avg upside 47 analysts	—	-0.1%	·
VERX Vertex	Mar 31, 2026	BUY	Buy +153.2% avg upside 24 analysts	—	+7.0%	·
OKUR OnKure Therapeutics	Dec 22, 2023	HOLD	Buy +507.7% avg upside 13 analysts	—	-38.4%	·
NEUP Neuphoria Therapeutics	Sep 28, 2023	BUY	Strong Buy +428.0% avg upside 6 analysts	—	-81.0%	·
PRAX Praxis Precision Medicines	Mar 03, 2023	HOLD	Strong Buy +45.8% avg upside 24 analysts	—	·	·
NERV Minerva Neurosciences	Dec 29, 2022	HOLD	Buy +90.9% avg upside 8 analysts	—	+307.3%	·

🔒 28 more ratings — with price targets, crowd consensus and our measured returns.

Free account unlocks every analyst's full coverage table.

Myles Minter — Frequently Asked Questions

How accurate are Myles Minter's stock ratings?

Based on the calls 13Foresight could measure, about 58% of Myles's ratings were profitable over a one-year hold, with an average return of +7.5% per rating, or +4.7% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.

How is Myles ranked on 13Foresight?

Myles Minter is currently ranked #977 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.

Which stocks does Myles cover?

Myles most recently has ratings on OVID, ANRO, IMUX, BHVN, BBIO, VRTX, SLN, AXSM, DNLI, ARCT, ALEC, VTGN and 21 more. See the full coverage table above for positions, price targets and our measured returns.

Where can I see other analyst ratings?

Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.

Myles Minter

Rating Distribution

Welcome to 13Foresight!